Condition: Solid Tumor, Adult · Metastatic Solid Tumor · Refractory Cancer · Sponsor: Sairopa B.V.
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).
This description comes directly from the study's public registry record.
Sairopa Clinical Team · 0031 85 90 26 939 · clinical@sairopa.com
Always discuss trial participation with your own doctor first.
| Henry Ford Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Washington University Medical Campus | St Louis, Missouri, United States | Recruiting |
| Gabrail Cancer & Research Center | Canton, Ohio, United States | Recruiting |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | Recruiting |
| Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame | Charleroi, Belgium | Recruiting |
| Hosp 12 de Octubre | Madrid, Spain | Recruiting |
| Hospital General Universitario Gergorio Maranon | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05856981